SignalSilence? HDAC4 siRNA I

• 产品编号：CST-7595S      品牌：CST       原厂货号：7595S
• 产品分类：DNA和RNA纯化 > RNA干扰 > RNAi Oligos > siRNA
• 应用分类：

描述：

SignalSilence® HDAC4 siRNA I抑制人源、小鼠和大鼠HDAC4蛋白的表达。来自 Cell Signaling Technology (CST)公司的SignalSilence® HDAC4 siRNA I可以帮助研究者通过RNA干扰去特异性抑制HDAC4蛋白表达，这种方法可以通过将双链RNA分子传递到细胞内从而使基因表达有选择的沉默。来自CST的所有的SignalSilence^®siRNA产品都是经过内部严格检测的，并且通过Western blot 分析证明确实能够减少目的蛋白的表达。通过三苯甲基分析每个碱基以监测寡核苷酸的合成，确保合适的配对效率。随后寡核苷酸通过亲和固相萃取法纯化。退火的RNA双链通过质谱分析来证实其精确的组成。每一批产品都通过质谱分析与前面的产品进行比较，来保证不同批次之间的最大一致性。CST公司推荐在细胞裂解前48到72小时转染100 nM HDAC4 siRNA I。转染步骤按照转染试剂说明书提供的步骤进行。遇到任何使用方面的问题，请随时联系CST。组蛋白尾部的乙酰化可引起染色质成为松散的构象，这允许转录因子更易接近DNA。组蛋白去乙酰化转移酶(histone acetyltransferases,HATs)的鉴定和它们的多种蛋白复合物在它们怎样酶促调节转录中已经有了重要的见解(1,2)。HAT复合物可与特异性靶基因上序列特异的激活蛋白发生相互作用。除了组蛋白之外，HATs能够使非组蛋白乙酰化，这就认为这些酶的多种功能(3)。与此相反，组蛋白去乙酰化可促进一个致密的染色质构象，并且典型地导致基因活性的抑制(4)。哺乳动物组蛋白去乙酰化酶能按照它们的类似与多种酵母去乙酰化酶划分成三类(5)。Class I蛋白 (HDACs 1、2、3和8)是与酵母Hda1样蛋白相关，并且class III蛋白是与酵母Sir2相关。目前HDAC活性的抑制剂已经被认为潜在的治疗癌症的药物(6,7)。

1. Marmorstein, R. (2001) Cell Mol Life Sci 58, 693-703.
2. Gregory, P.D. et al. (2001) Exp Cell Res 265, 195-202.
3. Liu, Y. et al. (2000) Mol Cell Biol 20, 5540-53.
4. Cress, W.D. and Seto, E. (2000) J Cell Physiol 184, 1-16.
5. Gray, S.G. and Ekström, T.J. (2001) Exp Cell Res 262, 75-83.
6. Thiagalingam, S. et al. (2003) Ann. N.Y. Acad. Sci. 983, 84-100.
7. Vigushin, D.M. and Coombes, R.C. (2004) Curr. Cancer Drug Targets 4, 205-218.

原厂资料：

Homology

Species predicted to react based on 100% sequence homology: Mouse, Rat

Specificity / Sensitivity

SignalSilence® HDAC4 siRNA I will inhibit human, mouse and rat HDAC4 exoression.

Description

SignalSilence® HDAC4 siRNA I from Cell Signaling Technology (CST) allows the researcher to specifically inhibit HDAC4 expression using RNA interference, a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. All SignalSilence® siRNA products from CST are rigorously tested in-house and have been shown to reduce target protein expression by western analysis.

Quality Control

Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.

Directions for Use

CST recommends transfection with 100 nM HDAC4 siRNA I 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.

Background

Acetylation of the histone tail causes chromatin to adopt an "open" conformation, allowing increased accessibility of transcription factors to DNA. The identification of histone acetyltransferases (HATs) and their large multiprotein complexes has yielded important insights into how these enzymes regulate transcription (1,2). HAT complexes interact with sequence-specific activator proteins to target specific genes. In addition to histones, HATs can acetylate nonhistone proteins, suggesting multiple roles for these enzymes (3). In contrast, histone deacetylation promotes a "closed" chromatin conformation and typically leads to repression of gene activity (4). Mammalian histone deacetylases can be divided into three classes on the basis of their similarity to various yeast deacetylases (5). Class I proteins (HDACs 1, 2, 3, and 8) are related to the yeast Rpd3-like proteins, those in class II (HDACs 4, 5, 6, 7, 9, and 10) are related to yeast Hda1-like proteins, and class III proteins are related to the yeast protein Sir2. Inhibitors of HDAC activity are now being explored as potential therapeutic cancer agents (6,7).

1. Marmorstein, R. (2001) Cell Mol Life Sci 58, 693-703.
2. Gregory, P.D. et al. (2001) Exp Cell Res 265, 195-202.
3. Liu, Y. et al. (2000) Mol Cell Biol 20, 5540-53.
4. Cress, W.D. and Seto, E. (2000) J Cell Physiol 184, 1-16.
5. Gray, S.G. and Ekström, T.J. (2001) Exp Cell Res 262, 75-83.
6. Thiagalingam, S. et al. (2003) Ann. N.Y. Acad. Sci. 983, 84-100.
7. Vigushin, D.M. and Coombes, R.C. (2004) Curr. Cancer Drug Targets 4, 205-218.

注意事项：

Storage: HDAC4 siRNA I is supplied in RNAse-free water.
Aliquot and store at -20ºC.